Mavenir Introduces Fixed Wireless Access Solution
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud, today announced the availability of its Fixed Wireless Access solution (FWA) combining Mavenir’s Open Virtualized RAN, Converged Packet Core and OpenBeam™ portfolio of radio units. This offering provides a competitive solution in a low-footprint deployment that leverages public and private cloud infrastructure. Mavenir’s FWA solution delivers high throughput, differentiated QoS control, geo-restriction, home-zoning, differentiated charging, advanced power savings, and many more features.
FWA offers consumers and businesses in urban and suburban areas with more competitive choices to select the best service that covers their needs at affordable prices.
“Fixed Wireless Access using LTE or 5G radio formats provides much more stable performance than the 802.11-based links that are popular today. In my testing, a CBRS-based LTE link has only 0.1% packet loss compared with 8.5% for an 802.11-based FWA link,” said Mobile Experts’ Joe Madden, Chief Analyst. “Four years ago, higher packet loss may have been acceptable, but today’s work-from-home environment requires a very stable, reliable link for video conferencing. For that reason, our forecasting anticipates a strong trend toward 3GPP technology in FWA, and Open RAN solutions will be popular due to their low cost.”
Mavenir’s FWA solution supports 4G, 5G NSA (non-standalone) and 5G SA deployments, supporting massive MIMO radio technology and 5G millimeter wave frequency bands to enable gigabit downlink speeds to multiple users in the same coverage area. This positions 5G FWA as a competitive alternative. Mavenir's FWA solution is delivered on converged infrastructure to provide a lean solution with maximum downlink throughput. It can be deployed on any cloud (public, hybrid and public), accelerating time to market and reducing CapEx and OpEx.
“5G and Open RAN transform the Fixed Wireless Access space to make it easier and more feasible to connect the unconnected and foster much needed competition,” said BG Kumar, President of Access Networks and Platforms, Mavenir. “The combination of Mavenir’s award-winning Converged Packet Core and Open Virtualized RAN solutions, with the OpenBeam broad portfolio of radios enables mobile operators to position themselves as an affordable and reliable alternative to cable and fiber deployments in rural, suburban and even urban settings”.
For rural areas, FWA provides higher downlink speeds than DSL and lower packet latency than most satellite internet service providersi. This brings access to new use cases that were not possible in rural areas before, such as telemedicine, online education, and work from home flexibility.
Mavenir’s FWA solution has been deployed by several customers, including 360 Communications, RINA Wireless, Triangle Communications, in the United States as well as Quickline in the United Kingdom.
For more information, visit the Mavenir Fixed Wireless Access Solution page.
Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
iCBRS-based FWA beats Starlink Performance
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005217/en/
Contact information
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Appoints Market Growth and Revenue Operations Leader, Dallas Olson to Chief Commercial Officer Role6.5.2024 17:30:00 CEST | Press release
NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced Dallas Olson as the company’s new Chief Commercial Officer, reporting to NetApp’s President, César Cernuda. Olson brings over 25 years of experience building high-performance teams responsible for planning, operations, enablement, engagement, and go-to-market strategies. As NetApp’s CCO, Olson will oversee sales strategy driving business growth in key areas including AI and Keystone through specialist teams, enhance market presence, optimize sales models, foster strategic partnerships, champion a customer-centric approach, and drive initiatives to maintain NetApp’s position as a market leader primed for accelerated growth. “We’re thrilled for Dallas to join NetApp at a time of momentum for the company as we empower enterprises to make their data infrastructure intelligent with unified data storage built for innovation in the era of AI," said César Cernuda, President at NetApp. “Olson's previous achievem
Nanochon closes $4M Series Seed Prime6.5.2024 17:00:00 CEST | Press release
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team. “We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.” Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilag
Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies6.5.2024 16:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies. “We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collabo
NanoTemper Brings Spectral Shift Technology to the Protein Production Market With Andromeda X, Enabling Biopharma and CROs to Increase Efficiency of Expression Screening for Recombinant Protein Targets6.5.2024 15:17:00 CEST | Press release
NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who now have the ability to optimize purification schemes for challenging, low-yield targets much faster, and with unprecedented insights on thermal stability during expression screening. “At NanoTemper, our vision of creating a world where every disease is treatable starts here, in early drug development. Without high-quality drug targets or protein therapeutics, researchers cannot realize this vision. So, we’ve adapted our reliable and trusted optics systems to provide valuable insights for those working to express and purify these critical t
Yubico’s Key Product Innovations Empower Enterprise Security and Phishing-Resistant Passwordless Authentication at Scale6.5.2024 15:00:00 CEST | Press release
Today Yubico (NASDAQ: YUBICO), the leading provider of hardware authentication security keys, announced the upcoming release of YubiKey 5.7 firmware for the YubiKey 5 Series, Security Key Series and Security Key Series - Enterprise Edition. With a focus on enterprise needs, these updates reinforce Yubico’s commitment to providing secure, simple, and scalable authentication solutions. Security keys with firmware 5.7 will be available to purchase in late May 2024, offering enhanced features such as improved PIN complexity, enterprise attestation, and expanded passkey credentials storage. These updates empower organizations to adopt passwordless-first, modern authentication, fostering phishing-resistant users worldwide. As part of Yubico’s goal of helping enterprises raise the bar for security with greater flexibility, the company also announced the availability of Yubico Authenticator 7 which will support the upcoming YubiKey 5.7 features. “Organizations are continuing to face a surge in